ADOBE SYSTEMS INCORPORATED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 87 Accounting for Uncertainty in Income Taxes During fiscal 2014 and 2013, our aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows (in thousands):
## Table 0 ##
As of November 28, 2014, the combined amount of accrued interest and penalties related to tax positions taken on our tax returns and included in non-current income taxes payable was approximately $14.6 million.
We file income tax returns in the U. S.  on a federal basis and in many U. S.  state and foreign jurisdictions.
We are subject to the continual examination of our income tax returns by the IRS and other domestic and foreign tax authorities.
Our major tax jurisdictions are Ireland, California and the U. S.  For Ireland, California and the U. S. , the earliest fiscal years open for examination are 2008, 2008 and 2010, respectively.
We regularly assess the likelihood of outcomes resulting from these examinations to determine the adequacy of our provision for income taxes and have reserved for potential adjustments that may result from the current examinations.
We believe such estimates to be reasonable; however, there can be no assurance that the final determination of any of these examinations will not have an adverse effect on our operating results and financial position.
In July 2013, a U. S.  income tax examination covering fiscal 2008 and 2009 was completed.
Our accrued tax and interest related to these years was $48.4 million and was previously reported in long-term income taxes payable.
We settled the tax obligation resulting from this examination with cash and income tax assets totaling $41.2 million, and the resulting $7.2 million income tax benefit was recorded in the third quarter of fiscal 2013.
The timing of the resolution of income tax examinations is highly uncertain as are the amounts and timing of tax payments that are part of any audit settlement process.
These events could cause large fluctuations in the balance sheet classification of current and non-current assets and liabilities.
We believe that within the next 12 months, it is reasonably possible that either certain audits will conclude or statutes of limitations on certain income tax examination periods will expire, or both.
Given the uncertainties described above, we can only determine a range of estimated potential decreases in underlying unrecognized tax benefits ranging from $0 to approximately $5 million.
NOTE 10.
RESTRUCTURING Fiscal 2014 Restructuring Plan In the fourth quarter of fiscal 2014, in order to better align our global resources for Digital Media and Digital Marketing, we initiated a restructuring plan to vacate our Research and Development facility in China and our Sales and Marketing facility in Russia.
This plan consisted of reductions of approximately 350 full-time positions and we recorded restructuring charges of approximately $18.8 million related to ongoing termination benefits for the positions eliminated.
During fiscal 2015, we intend to vacate both of these facilities.
The amount accrued for the fair value of future contractual obligations under these operating leases was insignificant.
Other Restructuring Plans During the past several years, we have implemented Other Restructuring Plans consisting of reductions in workforce and the consolidation of facilities to better align our resources around our business strategies.
As of November 28, 2014, we considered our Other Restructuring Plans to be substantially complete.
We continue to make cash outlays to settle obligations under these plans, however the current impact to our Consolidated Financial Statements is not significant.
Table of Contents Significant components of the Company’s deferred tax assets and liabilities are as follows
## Table 1 ##
Under ASC 740, Income Taxes, the Company can only recognize a deferred tax asset for the future benefit of its tax loss and credit carryforwards to the extent that it is “more likely than not” that these assets will be realized.
After considering all available positive and negative evidence, the Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that a portion of its tax loss carryforward will not be realized.
In determining the realizability of these assets, the Company considered numerous factors, including historical profitability, estimated future taxable income and the industry in which it operates.
The valuation allowance decreased $2.9 million in fiscal 2011 from fiscal 2010 primarily due to the expiration of certain federal and state net operating losses.
During fiscal years 2011, 2010 and 2009, the Company recorded reductions of $2.0 million, $1.1 million and $1.1 million, respectively, to goodwill related to the tax benefit of stock options exercised that had been assumed in acquisitions prior to the adoption of ASC 805.
As of September 24, 2011, the Company had gross federal, state and foreign net operating losses of $79.3 million, $4.5 million and $48.4 million respectively, and federal, state and foreign credit carryforwards of $4.5 million, $8.6 million and $2.7 million respectively, that it believes are more likely than not that they will be realized.
The federal and state net operating losses exclude $5.8 million and $16.9 million, respectively, of net operating losses, which the Company believes will expire unutilized.
The following table summarizes the expiration periods of the net operating losses and credit carryforwards:
## Table 2 ##
Table of Contents On April 2, 2008, the Company effected a two-for-one stock split in the form of a stock dividend to stockholders as of March 21, 2008.
Pursuant to the Amended and Restated Rights Agreement, the Company amended the terms of the rights issued and issuable under the agreement (“Rights”), effective as of April 3, 2008 (after the stock dividend), to reset the Rights such that each share of Common Stock is entitled to receive one Right, to retain the purchase price of each Right at $60 per Right, and to provide that each Right will entitle the holder to purchase one twenty-five thousandth of a share of Series A Junior Participating Preferred Stock (the “Series A Preferred Stock”).
Conforming changes have also been made to the Company’s certificate of designation for the Series A Preferred Stock to provide that each share of Series A Preferred Stock carries 25,000 times the dividend, liquidation and voting rights of the Company’s Common Stock.
Other modifications have also been made in the Amended and Restated Rights Agreement to update the agreement for certain developments, including the recent amendments to the Company’s by-laws permitting stockholders to hold and transfer shares of the Company’s capital stock in book entry form.
The expiration date of the Rights has remained unchanged at January 1, 2013.
Stock-Based Compensation Equity Compensation Plans The Company has one share-based compensation plan pursuant to which awards are currently being made—the 2008 Equity Incentive Plan.
The Company has four share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made—i) the 1995 Combination Stock Option Plan; ii) the 1997 Employee Equity Incentive Plan; iii) the 1999 Equity Incentive Plan; and iv) the 2000 Acquisition Equity Incentive Plan.
At the Company’s March 11, 2008 Annual Meeting of Stockholders, the Company’s 2008 Equity Incentive Plan (the “2008 Equity Plan”) was approved.
In connection with this approval, the Company’s 1999 Second Amended and Restated Equity Incentive Plan was terminated.
The purpose of the 2008 Equity Plan is to provide stock options, stock issuances and other equity interests in the Company to employees, officers, directors, consultants and advisors of the Company and its parents and subsidiaries, and any other person who is determined by the Board of Directors to have made (or is expected to make) contributions to the Company.
The 2008 Equity Plan is administered by the Board of Directors of the Company, and a total of 20 million shares were reserved for issuance under this plan.
As of September 24, 2011, the Company had approximately 8.2 million shares available for future grant under this plan.
The Company assumed certain other plans in connection with the Cytyc and Third Wave acquisitions, and no shares are available for future grant under these plans.
Grant-Date Fair Value Effective with the adoption of ASC 718, the Company elected to use a binomial lattice model to determine the fair value of its stock options.
The Company considers a number of factors to determine the fair value of options including the assistance of an outside valuation advisor.
Information pertaining to stock options granted during fiscal 2011, 2010 and 2009 and related assumptions are noted in the following table:
## Table 3 ##
Table of Contents full year of expenses for Sentinelle Medical (acquired in the fourth quarter of fiscal 2010), and higher compensation costs related to hiring additional personnel, annual salary increases, higher bonuses due to improved company performance and higher sales commissions for our breast biopsy business.
Diagnostics.
## Table 4 ##
Diagnostics revenues increased in fiscal 2011 compared to fiscal 2010 primarily due to the increase in product sales discussed above.
Operating income increased in fiscal 2011 compared to fiscal 2010 primarily due to the net gain of $84.5 million on the sale of the Makena intellectual property to KV in the second quarter of fiscal 2011 discussed above and an increase in gross margin in absolute dollars due to higher revenues.
Gross margin rates were 53.9% and 53.4% in fiscal 2011 and 2010, respectively.
These increases were partially offset by higher operating expenses attributable to the inclusion of TCT (acquired in the third quarter of fiscal 2011) and related integration costs and contingent consideration compensation expense of $17.6 million, and higher compensation costs related to hiring additional personnel, annual salary increases, and higher bonuses due to improved company performance.
GYN Surgical.

Tables referenced above, in order (Table 0 first):
<table><tr><td></td><td>2014</td><td>2013</td></tr><tr><td>Beginning balance</td><td>$136,098</td><td>$160,468</td></tr><tr><td>Gross increases in unrecognized tax benefits – prior year tax positions</td><td>144</td><td>20,244</td></tr><tr><td>Gross increases in unrecognized tax benefits – current year tax positions</td><td>18,877</td><td>16,777</td></tr><tr><td>Settlements with taxing authorities</td><td>-995</td><td>-55,851</td></tr><tr><td>Lapse of statute of limitations</td><td>-1,630</td><td>-4,066</td></tr><tr><td>Foreign exchange gains and losses</td><td>-3,646</td><td>-1,474</td></tr><tr><td>Ending balance</td><td>$148,848</td><td>$136,098</td></tr></table>
<table><tr><td></td><td>September 24, 2011</td><td>September 25, 2010</td></tr><tr><td>Deferred tax assets</td><td></td><td></td></tr><tr><td>Net operating loss carryforwards</td><td>$56,641</td><td>$76,365</td></tr><tr><td>Nondeductible accruals</td><td>17,767</td><td>8,776</td></tr><tr><td>Nondeductible reserves</td><td>8,400</td><td>9,038</td></tr><tr><td>Stock-based compensation</td><td>23,826</td><td>26,236</td></tr><tr><td>Research and other credits</td><td>13,207</td><td>12,141</td></tr><tr><td>Convertible notes issuance costs</td><td>1,283</td><td>1,410</td></tr><tr><td>Deferred gain</td><td>—</td><td>29,396</td></tr><tr><td>Nonqualified deferred compensation plan</td><td>7,324</td><td>6,093</td></tr><tr><td>Other temporary differences</td><td>4,267</td><td>4,500</td></tr><tr><td></td><td>132,715</td><td>173,955</td></tr><tr><td>Less: valuation allowance</td><td>-13,930</td><td>-16,798</td></tr><tr><td></td><td>$118,785</td><td>$157,157</td></tr><tr><td>Deferred tax liabilities</td><td></td><td></td></tr><tr><td>Depreciation and amortization</td><td>$-771,504</td><td>$-782,770</td></tr><tr><td>Debt discount on convertible notes</td><td>-100,538</td><td>-106,410</td></tr><tr><td>Original issue discount</td><td>-131,732</td><td>-146,101</td></tr><tr><td>Deferral on convertible notes exchange</td><td>-26,323</td><td>—</td></tr><tr><td>Investment in subsidiary</td><td>-6,507</td><td>-4,679</td></tr><tr><td></td><td>$-1,036,604</td><td>$-1,039,960</td></tr><tr><td></td><td>$ -917,819</td><td>$-882,803</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="6"> Period of Expiration</td></tr><tr><td> 2012-2017</td><td> 2018-2021</td><td> 2023-2027</td><td> 2028-2032</td><td> No expiration</td><td> Total</td></tr><tr><td>Federal net operating losses</td><td>$4,800</td><td>$25,488</td><td>$43,521</td><td>$5,504</td><td>—</td><td>$79,313</td></tr><tr><td>State net operating losses</td><td>268</td><td>9</td><td>1,122</td><td>3,123</td><td>—</td><td>4,522</td></tr><tr><td>Foreign net operating losses</td><td>—</td><td>—</td><td>885</td><td>35,122</td><td>12,395</td><td>48,402</td></tr><tr><td>Federal tax credits</td><td>—</td><td>2,596</td><td>1,665</td><td>254</td><td>—</td><td>4,515</td></tr><tr><td>Canadian tax credits</td><td>—</td><td>—</td><td>—</td><td>2,691</td><td>—</td><td>2,691</td></tr><tr><td>CA tax credits</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1,958</td><td>1,958</td></tr><tr><td>CT tax credits</td><td>136</td><td>1,454</td><td>207</td><td>—</td><td>1,464</td><td>3,261</td></tr><tr><td>MA tax credits</td><td>—</td><td>600</td><td>1,238</td><td>—</td><td>506</td><td>2,344</td></tr><tr><td>IN tax credits</td><td>394</td><td>646</td><td>—</td><td>—</td><td>—</td><td>1,040</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="3"> Years ended</td></tr><tr><td>September 24, 2011</td><td>September 25, 2010</td><td> September 26, 2009</td></tr><tr><td>Options granted</td><td>2,249</td><td>2,858</td><td>3,007</td></tr><tr><td>Weighted-average exercise price</td><td>$17.15</td><td>$15.65</td><td>$14.43</td></tr><tr><td>Weighted-average grant date fair value</td><td>$6.16</td><td>$5.87</td><td>$5.40</td></tr><tr><td>Assumptions:</td><td></td><td></td><td></td></tr><tr><td>Risk-free interest rates</td><td>1.0%</td><td>1.8%</td><td>2.0%</td></tr><tr><td>Expected life (in years)</td><td>4.2</td><td>3.9</td><td>4.0</td></tr><tr><td>Expected volatility</td><td>45%</td><td>47%</td><td>46%</td></tr><tr><td>Dividend yield</td><td>—</td><td>—</td><td>—</td></tr></table>
<table><tr><td></td><td colspan="4"> Years Ended</td></tr><tr><td></td><td>September 24, 2011</td><td>September 25, 2010</td><td colspan="2"> Change</td></tr><tr><td></td><td>Amount</td><td>Amount</td><td> Amount</td><td> %</td></tr><tr><td>Total Revenues</td><td>$571,263</td><td>$552,501</td><td>$18,762</td><td>3%</td></tr><tr><td>Operating Income</td><td>$170,693</td><td>$100,469</td><td>$70,224</td><td>70%</td></tr><tr><td>Operating Income as a % of Segment Revenue</td><td>30%</td><td>18%</td><td></td><td></td></tr></table>

Question: What's the sum of Investment in subsidiary Deferred tax liabilities of September 24, 2011, and Settlements with taxing authorities of 2013 ?
Answer: 62358
Reasoning program: add(6507.0,55851.0)